[PDF] Top 20 SPARC overexpression in primary tumors correlates with disease recurrence and overall survival in patients with triple negative breast cancer

... that SPARC down-regulation correlated with poor prognosis in patients with ...that patients with tumors classified as triple negative had the worst 10-year cumulative ... See full document

... positive/ER negative tumors while 58% were luminal (ER positive) ...in patients with basal-like tumors, followed by 70% among HER2 positive, and 47% among luminal subtype ...chemosensitivity, ... See full document

... as negative when <10% of tumor cells were posi- tively stained following the Dutch Breast Cancer ...defined negative in case of protein overexpression in an immunohistochemistry test ... See full document

... with breast cancer models, both alone or in combination with chemo- therapeutic ...pretreated patients (20 with TN tumors), 61 of whom were treated with anthracyclines and taxanes, Burstein ... See full document

... In recent years, there has been an increasing number of studies focused on understanding the molecular and bio- logical characteristics of TNBC. 19 Members of the MAT gene family are reported to play essential roles in ... See full document

... from breast cancer (CIDBC) of the training cohort were ...3. Patients younger than 40 years at diagnosis had the highest CIDBC ...while patients between 50 and 59 years old at diagnosis had ... See full document

... other cancer patients ...TNBC patients maybe helpful for early diagnosis, choice of treatment, de- cision of the degree of malignancy and risk prediction of ...and breast cancer risk ... See full document

... LncRNAs, which have been a focus of study recently, are segments of RNA that are more than 200 nucleotides in length with little translation capacity (i.e., non-coding RNAs). The total number of lncRNAs might be ... See full document

... 51,739 patients with newly diagnosed invasive ductal or lobular breast cancers were registered in the KBCS ...excluded patients with incomplete information regarding the ER, PR, and HER2 statuses; ... See full document

... the tumors had co-activation of MAPK and PI3K/AKT ...all patients who were more concerned in phase I trial. While MES tumors tend to frequently activate KRAS, BRAF, and RAS pathways, some may ... See full document

... Log rank (Mantel − Cox) tests were used to evaluate associations between DNA methylation levels and recurrence in IBCSG trial data. Because our institutional, case − control cohorts are selected for outcome, they ... See full document

... AZD2281 Astra Zeneca Kudos Single agent ICEBERG1 PO Advanced BRCA mutation ICEBERG1 NCT00494234. AZD2281 NCI Carbo / AZD2281 IV/PO Phase I BRCA mutation NCT00647062 AG014699 CRUK / Univ [r] ... See full document

... 2200 breast cancer patients on our electronic medical record (Mosaiq, Elekta, Crawley, United Kingdom) was undertaken; patients with TNBC treated with radiotherapy between 2006 and 2016 at the ... See full document

... and overexpression of the B7-H4 plasmids were constructed ...that breast cancer with axillary lymph node metastases was associated with the abnormal suppressor gene PTEN, which could play a ... See full document

... in patients with TNBC who underwent neoadjuvant anthracyclines-taxanes containing ...the overall pathologic complete response (pCR) rate was ...in patients with the BL2, MSL, and LAR subtypes (0%, ... See full document

... Li et al. and Tozbikian et al. showed that the levels of mesothelin expression in TNBC were an independent prognostic marker that correlates with low survival rates [8, 9]. However, two other studies failed ... See full document

... miRNA. Patients with miRNA expres- sion above or equal to the median values were characterized as having high expression, whereas pa- tients with miRNA expression below the median were characterized as having low ... See full document

... There is as yet no targeted therapy available for triple negative breast cancers. The poly (ADP-ribose) polymerases (PARPs) were investigated as targeted therapy for triple negative ... See full document

... of breast cancer that has limited treatment options ...of triple-negative breast cancer but its clinical significance is still unclear [14, ... See full document

... Patients were divided into 2 groups for statistical analysis based on whether or not they received PMRT. Comparisons of tumor and treatment characteristics between the PMRT and non-PMRT groups were performed using ... See full document